1
EXHIBIT 10.35A
[ABGENIX LOGO]
[ABGENIX LETTERHEAD]
Via Facsimile
Xx. Xxxxx Xxxx Xxxxxx
Manager, Corporate Development
MILLENNIUM BIOTHERAPEUTICS
000 Xxxxxxxx Xxxxx
Xxxxxxxxx, XX 00000
Re: Amendment No. 1 to Research Collaboration Agreement
Dear Xxxxx:
The purpose of this letter is to evidence the below-referenced amendments
to that certain Research Collaboration Agreement ("RCA"), dated as of September
29, 1998, between Abgenix, Inc. ("ABX") and Millennium BioTherapeutics, Inc.
("MBIO").
First, ABX and MBIO agree that the effective date of this amendment is
November 29, 1998.
Second, ABX and MBIO agree to amend Section 14 of the RCA to read in its
entirety as follows:
This Agreement shall remain in effect until July 31, 1999, or such
other date as the parties mutually agree upon in writing. Upon the
expiration of this Agreement, Sections 2(a) (other than the first sentence
thereof), 3, 5, 6, 7 and 10 shall survive.
ABX and MBIO agree that all other terms of the RCA remain the same and in
full force and effect.
2
To signify MBIO's agreement with the foregoing, please so indicate by
having an authorized representative of MBIO sign this letter in the space
provided below and returning it to Xxxxxxxxxxx X. Xxxx, Esq. via facsimile
((000) 000-0000).
Sincerely,
/s/ XXXXXXX X. XXXXX
-------------------------------------
Xxxxxxx X. Xxxxx, Ph.D.
Vice President, Corporate Development
Agreed and Acknowledged:
MILLENNIUM BIOTHERAPEUTICS, INC.
By: /s/ XXX XXXXXXX
---------------------------
Its.: Xxx Xxxxxxx, VP of
Pre-Clinical Development
---------------------------
Date: 1/14/99
---------------------------
